← Back to Search

CAR T-cell Therapy

ASCA101 IV for Solid Tumors

Phase 1

Waitlist Available

Research Sponsored by MetaFines

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up from first dose until documented disease progression or death, up to 36 months or until database cutoff date of 14jul2023]

Awards & highlights

Study Summary

This trial studies a new treatment to see if it's safe and effective in people with advanced cancer who have tried other treatments.

Eligible Conditions

Solid Tumors

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ from first dose until documented disease progression or death, up to 36 months or until database cutoff date of 14jul2023]

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~from first dose until documented disease progression or death, up to 36 months or until database cutoff date of 14jul2023]

This trial's timeline: 3 weeks for screening, Varies for treatment, and from first dose until documented disease progression or death, up to 36 months or until database cutoff date of 14jul2023] for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Maximum tolerated dose(MTD)

Secondary outcome measures

Duration of Response(DoR)

Objective response rate(ORR)

Progression Free Survival(PFS)

Trial Design

1Treatment groups

Experimental Treatment

Group I: ASCA101 IVExperimental Treatment1 Intervention

The study drug, ASCA101(300mg/vial), will be reconstituted in water for injection and diluted with saline to a dose calculated according to individual body surface area or body weight.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

ASCA101

2021

Completed Phase 1

~20

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

MetaFinesLead Sponsor

Media Library

ASCA101 (CAR T-cell Therapy) Clinical Trial Eligibility Overview. Trial Name: NCT05547906 — Phase 1

Solid Tumors Research Study Groups: ASCA101 IV

Solid Tumors Clinical Trial 2023: ASCA101 Highlights & Side Effects. Trial Name: NCT05547906 — Phase 1

ASCA101 (CAR T-cell Therapy) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05547906 — Phase 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the size of the sample group for this experiment?

"Affirmative, the information on clinicaltrials.gov conveys that this research is currently enrolling participants. The trial was initially announced on November 8th 2021 and refreshed most recently on October 26th 2022; 18 volunteers are being sought from a single site."

Answered by AI

What risks could patients encounter from an ASCA101 IV infusion?

"ASCA101 IV's safety is tentatively rated a 1 due to the preliminary nature of this Phase 1 trial and limited data concerning its efficacy."

Answered by AI

What is the principal aim of this experiment?

"The primary objective of this 28 day cycle trial is to identify the maximal tolerated dose (MTD). Secondary assessment criteria include measuring tumor responses through computerised tomography and magnetic resonance imaging scans, calculating an Objective Response Rate (ORR) using RECIST 1.1 standards, and determining a Duration of Response (DoR), determined by time from achieving either partial or complete response until disease progression or death as per RECIST 1.1 parameters."

Answered by AI

Are there any opportunities for prospective participants to join this medical experiment?

"Affirmative. According to the information on clinicaltrials.gov, recruitment for this trial is actively ongoing since its inception on November 8th 2021. 18 participants are required from a single medical centre in order to complete the study by October 26 2022"

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Evaluation of the Safety and Efficacy of ASCA101 in Patients With Advanced Solid Tumors

2021. "Evaluation of the Safety and Efficacy of ASCA101 in Patients With Advanced Solid Tumors". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05547906.